Neuropeptide y receptors in primary human brain tumors: Overexpression in high-grade tumors

Journal of Neuropathology and Experimental Neurology

Volumn 67, Issue 8, 2008, Pages 741-749

  Körner, Meike ^a   Reubi, Jean Claude ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

35S GTPFS binding autoradiography; Embryonal brain tumor; Glioblastoma; Neuropeptide Y receptors; Receptor autoradiography

Indexed keywords

GUANOSINE 5' O (3 THIOTRIPHOSPHATE); IODINE 125; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; PEPTIDE YY; SULFUR 35; ARGININE; BENZAZEPINE DERIVATIVE; DRUG DERIVATIVE; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; PEPTIDE; RADIOACTIVE IODINE;

ARTICLE; ASTROCYTOMA; AUTORADIOGRAPHY; BRAIN CORTEX; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; DISEASE SEVERITY; GENE OVEREXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MENINGIOMA; NERVE FIBER; NEURILEMOMA; NEUROECTODERM TUMOR; OLIGODENDROGLIOMA; PARAGANGLIOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR DENSITY; WORLD HEALTH ORGANIZATION; BINDING COMPETITION; CLASSIFICATION; DOSE RESPONSE; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; TISSUE DISTRIBUTION;

ARGININE; AUTORADIOGRAPHY; BENZAZEPINES; BINDING, COMPETITIVE; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; IODINE RADIOISOTOPES; PEPTIDES; PROTEIN BINDING; RECEPTORS, NEUROPEPTIDE Y; TISSUE DISTRIBUTION;

EID: 52249117226     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e318180e618     Document Type: Article

References (40)

1. Balasubramaniam A. Clinical potentials of neuropeptide Y family of hormones. Am J Surg 2002;183:430-34
2. Michel MC, Beck-Sickinger A, Cox H, et al. XVI. International Union of Pharmacology recommendations for the nomenclature of neuro-peptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev 1998;50:143-50
3. Reubi JC, Gugger M, Waser B, et al. Y1-mediated effect of neuropeptide Y in cancer: Breast carcinomas as targets. Cancer Res 2001;61:4636-41
4. Körner M, Waser B, Reubi JC. Neuropeptide Y receptor expression in human primary ovarian neoplasms. Lab Invest 2004;84:71-80
5. Körner M, Waser B, Reubi JC. High expression of NPY receptors in tumors of the human adrenal gland and extraadrenal paraganglia. Clin Cancer Res 2004;10:8426-33
6. Körner M, Waser B, Reubi JC. Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas. Int J Cancer 2005;115:734-41
7. Kitlinska J, Abe K, Kuo L, et al. Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res 2005;65:1719-28
8. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427
9. Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: Its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 1996; 125:26-34
10. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754-62
11. Sathornsumetee S, Rich JN. New treatment strategies for malignant gliomas. Expert Rev Anticancer Ther 2006;6:1087-104
12. Kneifel S, Cordier D, Good S, et al. Local targeting of malignant gli-omas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1- glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res 2006; 12:3843-50
13. Müller HL, Frühwald MC, Scheubeck M, et al. A possible role for somatostatin receptor scintigraphy in the diagnosis and follow-up of children with medulloblastoma. J Neurooncol 1998;38:27-40
14. Beutler D, Avoledo P, Reubi JC, et al. Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy. Cancer 2005;103:869-73
15. Yüksel M, Lutterbey G, Biersack HJ, et al. 111In-pentetreotide scintigraphy in medulloblastoma: A comparison with magnetic resonance imaging. Acta Oncol 2007;46:111-17
16. Merlo A, Hausmann O, Wasner M, et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90--labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): A pilot study in human gliomas. Clin Cancer Res 1999;5:1025-33
17. Kneifel S, Bernhardt P, Uusijárvi H, et al. Individual voxelwise dosimetry of targeted (90)Y-labelled substance P radiotherapy for malignant gliomas. Eur J Nucl Med Mol Imaging 2007;34:1388-95
18. Dumont Y, Jacques D, Bouchard P, et al. Species differences in the expression and distribution of the neuropeptide Y Y1, Y2, Y4, and Y5 receptors in rodents, guinea pig, and primates brains. J Comp Neurol 1998;402:372-84
19. Beck-Sickinger AG, Grouzmann E, Hoffmann E, et al. A novel cyclic analog of neuropeptide Y specific for the Y2 receptor. Eur J Biochem 1992;206:957-64
20. Inui A, Sano K, Miura M, et al. Evidence for further heterogeneity of the receptors for neuropeptide-Y and peptide-YY in tumor cell lines derived from neural crest. Endocrinology 1992;131:2090-96
21. Fabry M, Cabrele C, Hocker H, et al. Differently labeled peptide ligands for rapid investigation of receptor expression on a new human glioblastoma cell line. Peptides 2000;21:1883-93
22. Sovagó J, Dupuis DS, Gulyas B, et al. An overview on functional Véronique receptor autoradiography using [35S]GTPgammaS. Brain Res Brain Res Rev 2001;38:149-64
23. Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumors of the Central Nervous System. Lyon, France: IARC Press, 2007
24. Reubi JC, Heitz PU, Landolt AM. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: Evidence for different tumor subclasses. J Clin Endocrinol Metab 1987;65:65-73
25. Reubi JC, Horisberger U, Lang W, et al. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol 1989;134:337-44
26. Oka H, Jin L, Reubi JC, et al. Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP/vasoactive intestinal polypeptide receptor expression in human pituitary adenomas. Am J Pathol 1998;153:1787-96
27. Cabrele C, Wieland HA, Koglin N, et al. Ala31-Aib32: Identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y5-receptor. Biochemistry 2002;41:8043-49
28. Shaw JL, Gackenheimer SL, Gehlert DR. Functional autoradiography of neuropeptide Y Y1 and Y2 receptor subtypes in rat brain using agonist stimulated [35S]GTPgammaS binding. J Chem Neuroanat 2003;26: 179-93
29. Happe HK, Bylund DB, Murrin LC. Agonist-stimulated [35S]GTPgam-maS autoradiography: Optimization for high sensitivity. Eur J Pharmacol 2001;422:1-13
30. Mikkelsen JD, Larsen PJ, Kruse-Larsen C, et al. Immunohistochemical and chromatographic identification of peptides derived from proneur-opeptide Y in the human frontal cortex. Brain Res Bull 1993;31:415-25
31. Körner M, Reubi JC. NPY receptors in human cancer: A review of current knowledge. Peptides 2007;28:419-25
32. Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumors. Nat Rev Neurosci 2007;8:610-22
33. Przedborski S, Goldman S, Schiffmann SN, et al. Neuropeptide Y, somatostatin, and cholecystokinin neurone preservation in anaplastic astrocytomas. Acta Neuropathol (Berl) 1988;76:507-10
34. Chan-Palay V, Allen YS, Lang W, et al. Cytology and distribution in normal human cerebral cortex of neurons immunoreactive with antisera against neuropeptide Y. J Comp Neurol 1985;238:382-89
35. Körner M, Waser B, Reubi JC. NPY receptors in human sarcomas: High expression levels of Y1 in Ewing sarcoma family of tumors. Clin Cancer Res. In press.
36. Jacques D, Tong Y, Shen SH, et al. Discrete distribution of the neuro-peptide Y Y5 receptor gene in the human brain: An in situ hybridization study. Brain Res Mol Brain Res 1998;61:100-7
37. Grouzmann E, Meyer C, Burki E, et al. Neuropeptide Y Y2 receptor signalling mechanisms in the human glioblastoma cell line LN319. Peptides 2001;22:379-86
38. Allen JM, Hoyle NR, Yeats JC, et al. Neuropeptides in neurological tumours. J Neurooncol 1985;3:197-202
39. Fruhwald MC, O'Dorisio developmental tumors of the central and peripheral nervous system. Ann N Y Acad Sci 1998;865:420-26
40. Knerr I, Schuster S, Nomikos P, et al. Gene expression of adrenome-dullin, leptin, their receptors and neuropeptide Y in hormone-secreting and non-functioning pituitary adenomas, meningiomas and malignant intracranial tumours in humans. Neuropathol Appl Neurobiol 2001;27: 215-22